All articles by Staff Writer
Staff Writer
Deep Bio Announces Market Authorization from Swissmedic for DeepDx Prostate, Paving the Way for European Expansion
Deep Bio, a leader in artificial intelligence (AI)-powered cancer diagnostics, announced today that it has obtained marketing authorization from Swissmedic for DeepDx Prostate, its AI-powered prostate cancer diagnostic software.
Danaher to Provide Cepheid’s Tuberculosis Test to the Global Fund at Cost
Danaher Corporation (NYSE: DHR) (“Danaher”), a global science and technology innovator, today announced it will provide Cepheid’s Xpert® MTB/RIF Ultra diagnostic test cartridges for tuberculosis (TB) at Cepheid’s cost of $7.97 each to the Global Fund to Fight AIDS, TB and Malaria (“the Global Fund”) and to less-developed countries eligible for Cepheid’s Global Access Program1 to support greater access to high-quality TB testing. The Global Fund is the largest provider of financing and programs to combat TB globally, ensuring each year that millions of tests are distributed in countries where the need to improve access is greatest.
GT Molecular Launches Multiplexed Assay Kit for Respiratory Pathogen Detection on the Roche Digital LightCycler® System
GT Molecular, Inc., a company providing ultrasensitive PCR assays for wastewater-based epidemiology testing, pathogen detection, and cancer research is pleased to announce an agreement with Roche to provide a highly multiplexed respiratory panel for wastewater surveillance on the new Roche Digital LightCycler® System. This digital PCR assay kit co-quantifies respiratory pathogens SARS-CoV-2, influenza A, influenza B, and RSV, as well as an internal process control all within a single reaction well. The kit Is available for sale starting today.
Innovative diagnostics and the use of AI allow individualised approaches in performance medicine, prevention of injuries and therapy
High calibre speakers at the MEDICA MEDICINE + SPORTS CONFERENCE illuminate new methods and their practical uses
QIAGEN launches API to streamline access to world-leading biomedical data for AI integration
Venlo, the Netherlands, and Redwood City, California, September 11, 2023 – QIAGEN Digital Insights, the bioinformatics business of QIAGEN, today announced the launch of an application programming interface (API) to streamline access for customers from pharma, biotech and academia to its QIAGEN Biomedical Knowledge Base, and enable easy integration of the data into their internal systems.
US FDA Grants Emergency Use Authorisation For ViraDx™
Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce that the US Food and Drug Administration (FDA) has granted Emergency Use Authorisation (EUA) and a CLIA Waiver (Clinical Laboratory Improvement Amendments) for the ViraDx test which is a combined COVID-19/Flu A/Flu B rapid POC test.
Bruker’s New NeuraLeap Delivers Unprecedented Imaging Speed Across Optical Planes
Novel Use of Digital Micromirror Device Enables Variable Depth-of-Field Collection for Advanced Neuroscience Research
MEDICA LABMED FORUM: four exciting topic days around hot issues, current trends and innovations in laboratory medicine
Important ideas for the entire health market
Bio-Rad Launches First StarBright™ Red Dye and Extends Range of Antibody Markers Conjugated to StarBright Dyes to Enhance Multiplex Flow Cytometry and Research Capabilities
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the 29th StarBright Dye, StarBright Red 670, and an expansion of its current range with 29 additional highly validated antibodies conjugated to StarBright Blue 700 and StarBright Violet 610 Dyes. Including additional human and mouse targets and introducing dog, cow, and pig targets, the new range provides greater choice and flexibility in conventional and full-spectrum multicolor flow cytometry panels, expanding research capabilities across veterinary immunology research.
QIAGEN Global Oncohematology Summit 2023 – Improving patients’ lives through testing and research
QIAGEN will host the Global Oncohematology Summit 2023, held on September 13 and 14, under the theme “I Can: Improving Patients’ Lives Through Oncohematology Testing and Research”. The virtual event unites experts and patients from around the globe to discuss the latest advances and challenges in oncohematology testing, blood cancer clinical care, and research, focusing on improving patient outcomes. Emphasizing the utmost importance of patients’ perspectives, the summit will feature their testimonies, bringing their voices and considerations to the forefront of the discussion.